Cardiac Electrophysiology Innovator AcorPulse Completes Nearly RMB 200 Million Series A+ Financing

Feb 07, 2024 14:04 CST Updated 14:04

AccuPulse

Developer of products in the field of cardiac electrophysiology

▎Edited by the WuXi AppTec content team

News on February 7, Cardiac Electrophysiology CompanyAccuPulseAnnounced the completion of nearly 200 million yuan in Series A+ financing. This round of financing was led byShengshi Investment Management's Shaoxing Binhai New Area Biomedical Industry Equity Investment FundAndShanghai Biopharmaceutical FundCo-led the investment.AccuPulse Medical Technology Co.Ltd was founded in November 2020, and is committed to becoming aCardiac ElectrophysiologyA platform-based innovation technology company in the field, thereby treating atrial fibrillation and other arrhythmia diseases and improving patients' quality of life.

According to the introduction in AccuPulse's press release, the company has independently developedPulsed Electric Field Ablation（PFA）Technology, with atrial fibrillation ablation as the entry point, took the lead in developing a pulsed-field ablation system and ablation catheter. In April 2023, they completed the enrollment of all participants for the clinical trial and are currently in the 12-month postoperative long-term follow-up stage.The results of the interim analysis have already met the criteria for early success set by the clinical protocol., showing that the product has better safety and effectiveness.

In addition, AccuPulse has further developed3D Mapping and Navigation SystemAnd new supporting tools, hoping to create an integrated solution for the development of active devices and supporting consumables for atrial fibrillation pulse ablation. This three-dimensional mapping system innovatively integrates an intelligent magnetic and electric dual positioning system, which will combine with the next-generation intracardiac echocardiography (ICE) function in the future to achieve ultrasound magnetic and electric triple positioning technology.This technology will be perfectly integrated with the pulsed ablation system, effectively eliminating clutter and noise issues, addressing the challenges of precise positioning and contact of pulsed ablation catheters, and is expected to improve surgical success rates while reducing operation time., bringing patients a safer, more effective, and more precise treatment experience. Currently, the three-dimensional mapping system has completed design finalization and is undergoing system verification. Multiple animal experiments of various kinds have already been completed, and it is about to enter the type inspection phase.

Prosperity Fund PartnerMs. Li DanSaid: "Pulsed electric field ablation has demonstrated therapeutic advantages over existing radiofrequency ablation and cryoablation in the field of cardiac electrophysiology, as verified in clinical trials. It is one of the important surgical treatment methods for the future. AccuPulse has established a professional, international team between China and the U.S., with deep expertise in pulsed electric field ablation and 3D mapping, and has already developed a diverse product pipeline. The company has shown extremely high execution efficiency in product development. We believe that AccuPulse will continue its efforts to bring excellent products and treatment solutions to the field of cardiac electrophysiology."

Dr. Liang Weibin, Partner of Shanghai Biomedical FundRepresent,AccuPulseWith excellent execution, significant progress has been made in product development, clinical trials, and team building, with plans to complete within this year.PFAClinical Follow-up of Patients Enrolled in Product Registration Clinical TrialsAndFDA Submission for 3D Mapping System in the United States。With the successive approvals of PFA products in China and the United States, the field of cardiac electrophysiology is set to embrace newer and better treatment options, and the penetration rate of catheter ablation surgeries based on 3D mapping technology will further increase. AccuPulse is believed to be capable of providing comprehensive treatment solutions based on green electrophysiology technology for a wide range of patients, becoming an important emerging force in the field of cardiac electrophysiology in China and even globally.

References:

[1] AccuPulse Completes Nearly 200 Million Yuan in Series A+ Financing, Accelerating the Localization of Pulse Ablation and 3D Mapping Systems in China. Retrieved Feb 7, 2024, from https://mp.weixin.qq.com/s/eyc6MDpc8E9r_W9EjeI4lA

This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share it on their social media feeds. For authorization to repost, please contact us via a message on the "MedView" WeChat Official Account. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.